FDA Approves Targeted Radionuclide Therapy for Earlier Use in Metastatic Prostate Cancer

For decades, a diagnosis of metastatic prostate cancer came with a predictable and frustrating trajectory. Patients would start on hormone-blocking therapies, which work exceptionally well initially by starving the tumors of the testosterone they need to grow. But the cancer almost inevitably adapts, outsmarting the drugs and resuming its spread, leaving patients with limited options and a ticking clock.

That timeline is now being fundamentally rewritten. On July 31, 2026, the U.S. Food and Drug Administration (FDA) approved the targeted radionuclide therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for earlier use in patients with metastatic hormone-sensitive prostate cancer.[1][2]

Previously, this powerful radioactive drug was reserved as a later-line option—only available after patients had exhausted hormone therapies and, in some cases, chemotherapy. Now, it can be administered right alongside initial hormone treatments, striking the cancer with a dual mechanism before it has the chance to build resistance.[3][6]

"The treatment landscape for metastatic hormone-sensitive prostate cancer is evolving, and this approval reflects a growing recognition that earlier treatment intensification matters," noted Dr. Michael J. Morris, a prostate cancer specialist who helped lead the clinical trials. By nearly doubling the eligible patient population, the decision marks a significant shift toward proactive, precision care.[1][4]

To understand why this is a breakthrough, it helps to look at how the drug works. Pluvicto belongs to an emerging class of treatments known as theranostics, which pairs diagnostic imaging with targeted therapy. The drug is an intravenous radioligand therapy that combines a targeting compound with a therapeutic radioactive particle, lutetium-177.[1][5]

The targeting compound acts like a homing beacon, specifically seeking out prostate-specific membrane antigen (PSMA)—a protein found in abundance on the surface of more than 80% of prostate cancer cells. Once it binds to the PSMA receptor, the drug is drawn directly to the tumor.[1][7]

Inside the tumor microenvironment, the lutetium-177 payload releases beta radiation. This localized energy emission damages the cancer cell's DNA, disrupting its ability to replicate and triggering cell death, while largely sparing the surrounding healthy tissue.[1][6]

The FDA's decision was driven by the results of the global Phase III PSMAddition clinical trial, which enrolled over 1,100 patients. Participants were randomized to receive either the standard of care—an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy—or the standard of care combined with Pluvicto.[2][5]

The addition of the radioligand therapy yielded striking results. Patients receiving the combination experienced a 33% reduction in the risk of radiographic disease progression or death compared to those on hormone therapy alone. This means the time before scans showed the cancer growing or spreading was significantly extended.[1][3][4]

For patients and their families, this approval translates into a critical new question for their oncology team: "Am I a candidate?" Eligibility hinges on a specialized imaging test called a PSMA PET scan, which confirms whether the patient's tumors express enough of the PSMA protein for the drug to find its target.[2][3]

If eligible, patients receive Pluvicto as an intravenous infusion once every six weeks for up to six doses. Because the treatment involves radioactive material, it must be administered by specialized nuclear medicine physicians or radiation oncologists at equipped facilities, which can pose logistical challenges for patients in rural areas.[3][7]

While the benefits are substantial, the treatment is not without side effects, and oncologists must weigh the added toxicity. The trial data showed that adding Pluvicto increased the rate of severe adverse events to 50.7%, compared to 43% for those on hormone therapy alone.[1][4]

Patients commonly reported dry mouth, fatigue, nausea, and anemia. The dry mouth occurs because salivary glands also express low levels of the PSMA protein, inadvertently attracting some of the radioactive drug, while the anemia is a known consequence of radiation affecting the bone marrow.[1][7]

Researchers are still tracking the trial participants to determine the ultimate impact on overall survival—the gold standard of cancer research. While early trends are promising and show a favorable trajectory, the final survival data is still maturing, representing a key area of ongoing study.[4][6]

Ultimately, this approval represents a paradigm shift in prostate cancer care. By moving precision radiation to the front lines, oncologists are no longer waiting for the disease to outsmart standard treatments, offering men a proactive strategy to maintain their quality of life and keep the cancer at bay for longer.[3][4]